Sensei Biotherapeutics Inc (SNSE)
Official siteBIOTECHNOLOGY
Last updated: Jun 15, 2026 at 5:00 PM ET
Sensei Biotherapeutics Inc (SNSE) Financials: Revenue, Profit and Cash Flow
Sensei Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$21.09M, operating cash flow was -$20.45M and free cash flow was -$20.47M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$170.24M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $22.29M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Cost of revenue | N/A | $551.00K | $571.00K | $1.81M | $685.00K | $209.00K | $73.00K | $44.00K |
| Gross profit | N/A | -$551.00K | -$571.00K | -$1.81M | -$685.00K | -$209.00K | -$73.00K | -$44.00K |
| Research and development | $10.96M | $18.63M | $18.30M | $30.38M | $21.66M | $11.92M | $8.35M | $8.23M |
| Operating income | -$22.29M | -$31.66M | -$37.06M | -$50.19M | -$37.48M | -$19.45M | -$12.44M | -$12.74M |
| Net income | -$21.09M | -$30.16M | -$34.10M | -$48.81M | -$36.79M | -$20.10M | -$16.74M | -$13.04M |
| EBITDA | -$20.91M | -$29.52M | -$33.39M | -$48.84M | -$35.44M | -$18.20M | N/A | -$12.70M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | -$4.85M | $0 | $0 | $544.00K | $0 | $0 | $0 | $2.85M | $0 | $0 |
| Gross profit | -$132.96M | $67.00K | N/A | -$37.00K | -$30.00K | -$139.00K | -$140.00K | -$135.00K | -$137.00K | -$135.00K | -$455.00K | -$491.00K |
| Operating income | -$170.63M | -$4.96M | -$4.85M | -$5.21M | -$7.27M | -$7.32M | -$7.82M | -$7.79M | -$8.73M | -$8.14M | -$7.74M | -$10.19M |
| Net income | -$170.24M | -$4.72M | -$4.57M | -$4.94M | -$6.86M | -$7.77M | -$7.25M | -$7.14M | -$7.99M | -$7.41M | -$7.12M | -$9.39M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.45M by $7.22M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $22.90M | $45.36M | $74.37M | $118.38M | $153.22M | $21.43M | $1.22M | $1.85M |
| Current assets | $21.51M | $41.93M | $67.25M | $108.59M | $148.54M | $20.08M | $502.00K | $1.28M |
| Cash and equivalents | $8.67M | $9.99M | $13.01M | $17.80M | $7.16M | $16.60M | $251.00K | $653.00K |
| Total liabilities | $4.31M | $6.97M | $9.48M | $14.97M | $6.71M | $5.54M | $69.88M | $55.33M |
| Short-term debt | $1.45M | $2.32M | $2.44M | $2.13M | $680.00K | $32.00K | $16.05M | $696.00K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $567.00K | N/A | $4.05M |
| Shareholder equity | $18.59M | $38.39M | $64.89M | $103.41M | $146.51M | $15.89M | -$68.66M | -$53.48M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $205.38M | $22.90M | $27.59M | $31.78M | $38.27M | $45.36M | $53.25M | $59.80M | $66.69M | $74.37M | $81.66M | $89.58M |
| Total liabilities | $14.19M | $4.31M | $4.58M | $4.47M | $6.29M | $6.97M | $7.47M | $7.61M | $8.22M | $9.48M | $10.66M | $10.38M |
| Cash and equivalents | $152.32M | $8.67M | $10.56M | $12.56M | $9.88M | $9.99M | $19.13M | $11.89M | $10.96M | $13.01M | $11.34M | $10.23M |
| Shareholder equity | $191.19M | $18.59M | $23.01M | $27.31M | $31.99M | $38.39M | $45.78M | $52.19M | $58.47M | $64.89M | $71.00M | $79.20M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.45M | -$24.67M | -$32.02M | -$39.03M | -$30.26M | -$17.70M | -$8.57M | -$10.31M |
| Capital expenditures | $16.00K | $146.00K | $180.00K | $321.00K | $2.03M | $1.21M | $53.00K | $31.00K |
| Free cash flow | -$20.47M | -$24.82M | -$32.20M | -$39.35M | -$32.28M | -$18.91M | -$8.62M | -$10.34M |
| Investing cash flow | $19.77M | $22.44M | $38.41M | $49.95M | -$143.12M | -$1.40M | -$53.00K | -$31.00K |
| Financing cash flow | -$645.00K | -$787.00K | -$11.17M | -$287.00K | $163.94M | $35.45M | $8.22M | $750.00K |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.73M | -$3.86M | -$3.59M | -$5.91M | -$7.09M | -$5.79M | -$5.47M | -$5.79M | -$7.62M | -$6.16M | -$4.66M | -$9.46M |
| Capital expenditures | $6.00K | $0 | $0 | $16.00K | $0 | $0 | $0 | $109.00K | $37.00K | $0 | $0 | $29.00K |
| Free cash flow | -$10.74M | -$3.86M | -$3.59M | -$5.92M | -$7.09M | -$5.79M | -$5.47M | -$5.90M | -$7.65M | -$6.16M | -$4.66M | -$9.49M |
Frequently Asked Questions About SNSE
What is Sensei Biotherapeutics' annual revenue?
Sensei Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Sensei Biotherapeutics profitable?
No. Sensei Biotherapeutics reported net income of -$21.09M for the fiscal year ended Dec 31, 2025.
How much free cash flow does SNSE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$20.45M minus capital expenditures of $16.00K produced free cash flow of -$20.47M.
How much debt does Sensei Biotherapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.45M and cash and equivalents of $8.67M.
SNSE pages: Overview, Financials